Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mestranol is a synthetic estrogen and the 3-methyl ether of ethinylestradiol. It is a biologically inactive prodrug that is demethylated in the liver to form ethinylestradiol, its active metabolite. Mestranol was one of the first estrogens used in combination oral contraceptives and has also been used for menopausal hormone therapy and treatment of menstrual disorders. Its primary mechanism involves binding to and activating estrogen receptors after conversion to ethinylestradiol, leading to suppression of gonadotropins (FSH and LH), inhibition of ovulation, changes in cervical mucus viscosity, and endometrial alterations that prevent pregnancy[2][4][7]. Mestranol has also been studied as a male contraceptive but was not pursued due to unacceptable side effects[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mestranol.